-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $82

Benzinga·05/08/2026 18:14:26
Listen to the news
RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and raises the price target from $80 to $82.